TG Therapeutics (NASDAQ:TGTX) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen upgraded shares of TG Therapeutics (NASDAQ:TGTX) from a hold rating to a buy rating in a research report report published on Sunday.

A number of other equities analysts also recently commented on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday, December 8th. JPMorgan Chase & Co. raised their price target on shares of TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. HC Wainwright initiated coverage on TG Therapeutics in a research note on Monday, October 6th. They issued a “buy” rating and a $60.00 price objective on the stock. Finally, B. Riley raised TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.25.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $31.35 on Friday. TG Therapeutics has a 12 month low of $25.28 and a 12 month high of $46.48. The company has a market capitalization of $4.98 billion, a P/E ratio of 11.28 and a beta of 2.01. The stock has a 50 day moving average of $32.91 and a two-hundred day moving average of $33.66. The company has a current ratio of 3.82, a quick ratio of 2.89 and a debt-to-equity ratio of 0.40.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $2.19. The business had revenue of $161.71 million during the quarter, compared to analyst estimates of $152.12 million. TG Therapeutics had a return on equity of 133.24% and a net margin of 84.13%.TG Therapeutics’s revenue was up 92.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.02 earnings per share. As a group, equities analysts expect that TG Therapeutics will post 0.08 EPS for the current year.

Insider Transactions at TG Therapeutics

In related news, Director Yann Echelard sold 5,000 shares of TG Therapeutics stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $32.57, for a total value of $162,850.00. Following the completion of the transaction, the director directly owned 223,816 shares in the company, valued at approximately $7,289,687.12. The trade was a 2.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 10.64% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TGTX. IFP Advisors Inc increased its holdings in shares of TG Therapeutics by 3.2% in the 3rd quarter. IFP Advisors Inc now owns 196,717 shares of the biopharmaceutical company’s stock worth $7,123,000 after buying an additional 6,020 shares during the last quarter. Swiss Life Asset Management Ltd purchased a new position in TG Therapeutics in the third quarter worth $251,000. Cantor Fitzgerald L. P. increased its stake in TG Therapeutics by 3.2% in the third quarter. Cantor Fitzgerald L. P. now owns 32,000 shares of the biopharmaceutical company’s stock valued at $1,156,000 after acquiring an additional 1,000 shares during the last quarter. Penn Capital Management Company LLC raised its position in TG Therapeutics by 17.6% during the third quarter. Penn Capital Management Company LLC now owns 521,260 shares of the biopharmaceutical company’s stock valued at $18,877,000 after purchasing an additional 77,895 shares in the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new position in shares of TG Therapeutics in the 3rd quarter worth about $559,000. Institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.